The low titer and incidence of autologous antibody to melanoma has hampered its evaluation. Through acid dissociation and ultrafiltration of serum, we have been able to augment the autologous immune response in 9 of 10 patients studied. This result suggests that autologous antibody is present in most patients with melanoma, but is obscured by circulating antigen and the formation of immune complexes. Because native antibody and antibody derived from circulating immune complexes are produced by the host against physiologically relevant antigens, correlations can be made to clinical course. Serological studies of three patients with melanoma were performed with serum samples obtained over many months; these studies demonstrated correlations with tumor progression and clinical course.
Introduction
Over the past several years various antibodies have been used to detect tumor-associated antigens of melanoma and other tumors. These antibodies have included polyclonal xenogeneic and allogeneic antisera (1-7) and, more recently, monoclonal murine and human antibodies (8) (9) (10) (11) (12) (13) (14) . Numerous cell surface antigens have been described using these probes, which are beginning to define an "antigenic map" of various tumors. We have focused our efforts on the autologous immune response to melanoma. These host-derived antibodies may detect antigens not previously identified by heteroantisera. Equally important, because autologous antibodies are produced against physiologically relevant antigens, they may increase our understanding of the nature of the host's immune response and its relationship to disease status.
The study of the autologous immune response to melanoma has been hampered by the low incidence and titer of these antibodies. In native sera, we and others have found low-titer autologous antibody to melanoma in one-third of melanoma patients (15) (16) (17) (18) (19) . Our failure to detect autologous antibody to melanoma more fiequently led us to postulate that this might be due to circulating antigen and the formation of immune complexes. To pursue this theory, we modified a technique reported by Sjogren et al., (20) in order to dissociate antigen from antibody by acid exposure, followed by ultrafiltration. We have recently reported that this technique enhanced autologous antibody reactivity in six of the seven cases we studied (19) .
Preliminary work suggests that immune complexes are a relevant and accessible source of autologous antibody and antigen. There is a substantial body of literature describing the presence of elevated levels of immune complexes in malignancy (21-23). Immune complex levels have been correlated with disease status, tumor burden, and prognosis (24, 25 (28) . All tests were done in duplicate. 50 M1 of test serum was mixed with 100 ,ul of 0.2 M EDTA, pH 7.5, and incubated 30 min at 37°C. Tubes were then placed on ice and 50 Mul of 125I-Clq followed by I ml of 3% polyethylene glycol were added and allowed to stand for I h. All tubes were spun at 1,500 g for 20 min at 4°C. The supernatant was completely discarded and the radioactivity of the precipitate counted.
'251-Clq binding was calculated in the same fashion as the Raji cellbinding assay.
Results
Acid dissociation and ultrafiltration of sera. Native sera from 10 patients were subjected to acid dissociation and ultrafiltration. Previously, only three sera demonstrated reactivity against autologous cultured melanoma cells as tested by protein A hemadsorption. After acid dissociation and ultrafiltration, 9 of 10 sera showed enhanced IgG reactivity against melanoma.
These results are shown in Table I . As reported previously (19) , sera from six normal individuals showed no reactivity to melanoma cells before or after acid dissociation and ultrafiltration.
Analysis of system Y-Mel 83:070. Before acid dissociation Table II .
Serial autologous studies Serial autologous studies were performed on three autologous systems. Sera were obtained at 1-4-mo intervals and tested before and after acid dissociation and ultrafiltration against After acid dissociation and ultrafiltration persistently elevated titers were seen. The one significant drop in titer may be related to a specific episode. These results are illustrated in Fig. 2 .
System Y-Mel 82:550. In this patient with resected stage II melanoma, a rise in autologous antibody detectable in native serum paralleled the clinical appearance of vitiligo. The titer of the acid-dissociated and ulhrafiltered serum fraction remained elevated throughout as illustrated in Fig. 3 .
System Y-Mel 81:710. Serial studies of this patient with metastatic melanoma were performed. While native sera showed no rise in autologous antibody titer, acid-dissociated and ultrafiltered sera demonstrated a rise in titer that paralleled disease progression. Of note are two significant drops in titer of the derived serum; both followed the administration of human leukocyte interferon for periods of 7 Immune complex detection The Raji cell assay was used to detect immune complexes in all three serial studies. In all three cases no significant rise in circulating immune complex levels was seen when compared to 15 
Discussion
The definition and characterization of melanoma cell surface antigens has been the goal of studies using monoclonal, Fig. 2 antibodies directed at melanoma, as well as cultured melanocytes (32) (33) (34) . It is unclear what the incidence of antibodies to melanocytes or melanoma is among melanoma patients. Prior investigations have only rarely found antibody to melanoma or melanocytes among patients with vitiligo. The development of vitiligo in patients with melanoma has been considered to be an indication of improved prognosis (35) . This might be due to the development of a host immune response directed against both melanocytes and melanoma cells. Notably, native serum antibody titer rose against autologous melanoma, YMel 82:550, while no rise in the titer of serum antibody dissociated by exposure to acid and ultrafiltered, was found. One explanation may be that in this setting, the total pool of antibody that is contained free in serum and bound in immune complexes may be relatively constant, and the appearance of free antibody may reflect a decrease in antigen.
Studies of melanoma Y-Mel 81:710 demonstrate a relationship of autologous antibody to progressive disease and interferon therapy in a patient with metastatic melanoma (Fig.  4) . A large burden of tumor antigen may have obscured changes in native antibody titer. Two significant drops in the titer of antibody retrieved after acid dissociation and ultrafiltration occurred following therapy of this patient with human leukocyte interferon (29). Similar reductions of retrievedantibody titer during interferon treatment on two occasions makes it doubtful that these were random fluctuations or unrelated events. Interferon is capable of inhibiting antibody production and other protein synthesis by B cells. Humoral and cellular immunity have been shown to be susceptible to interferon modulation in a time-dependent fashion (36) (Table II) (19) . Comparison between the three systems reveals a similar range of reactivity. Cross-reactivity between all three antibodies is noted as well. Pfreundschuh et al. (26) noted cross-reactivity of antibody against the astrocytoma antigen (AJ) when surveyed against allogeneic astrocytomas, neuroblastomas, sarcomas, and a mixed mesodermal tumor. Cross-reactivity between the AJ astrocytoma antigen and the AH melanoma antigen described by Shiku et al. (17) was implied, although a direct comparison has not been presented. It is possible that the three autologous systems reported here are detecting a similar antigen and that this antigen is also related to those reported by others (17, 26) . This may be determined by immunochemical analysis of these antigens that is currently underway.
Circulating immune complex levels in these patients exhibited no simple relationship to antibody titers. This may be a reflection of the imperfection of the assays available at present for immune complexes. Most assays detect larger, complementbinding immune complexes preferentially. No assay currently available reliably detects small noncomplement binding immune complexes as might be found in patients with malignancy and large quantities of circulating antigen. Alternative approaches of potential value currently under evaluation include precipitation of immune complexes by polyethylene glycol and subsequent acid dissociation and ultrafiltration or adsorption by lectins, followed by elution using appropriate sugars or physical means.
The role autologous antibody and circulating immune complexes play in the host response to cancer remains to be determined. Circulating immune complexes and tumor antigen have been implicated in immunosuppression (37) (38) (39) . It is unknown whether the antigen and antibody detected in this study are a reflection of the host's response to malignancy or are causally involved in the modification of that response. These results demonstrate that autologous antibody reactivity is detectable, but obscured in the serum of most patients with melanoma. Further, new results reported here correlate clinical course with the serum studies of native and derived autologous antibody. Serial studies provide a unique probe through which we will be able to define the physiologic relevance of autologous antibody in malignant disease.
